Episode Details

Back to Episodes
Valeo Pharma (VPH:CSE) Reported Record Q3-21 Revenue of $5.7 Million, up 280% Vs. Q3-20

Valeo Pharma (VPH:CSE) Reported Record Q3-21 Revenue of $5.7 Million, up 280% Vs. Q3-20

Season 3 Episode 154 Published 5 years, 1 month ago
Description

Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market. This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.  

The company recently released Q3 results and highlights:  

•  Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter. •  Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
•  Record 9 months revenues at $10.2 million , up 94%.
•  Private and public reimbursement coverage expanding for Redesca®
•  New corporate structure completed with full commercial activities ongoing for Redesca®, Enerzair® Breezhaler® and Atectura® Breezhaler® As you can see above, Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak. 

As a result, the company estimates annual revenue of $160M by 2025. Now sit back, relax and watch this powerful interview with Steve Saviuk CEO of Valeo Pharma.

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us